Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, is taking place from the 19–23 October. Stay tuned here for the latest data straight from the experts, including Phase III trial updates, the first prospective study of treatment sequencing in mCRPC, and coverage of all the late-breaking abstracts.

ESMO 2018

19–23 October 2018 | Munich, Germany

ESMO 2018

19–23 October 2018 | Munich, Germany

The European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, is taking place from the 19–23 October. Stay tuned here for the latest data straight from the experts, including Phase III trial updates, the first prospective study of treatment sequencing in mCRPC, and coverage of all the late-breaking abstracts.

Clinical trial updates on patient responses with triplet therapy 2:06
Clinical trial updates on patient responses with triplet therapy
Jeffrey Weber • 4 Jan 2019
Unmet clinical needs for platinum-resistant ovarian cancer patients 1:41
Unmet clinical needs for platinum-resistant ovarian cancer patients
Domenica Lorusso • 29 Nov 2018
Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo 4:25
Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
Thomas Powles • 29 Nov 2018
Treating oligometastatic CRPC with radiation to delay hormonal therapy 2:49
Treating oligometastatic CRPC with radiation to delay hormonal therapy
Joe O'Sullivan • 29 Nov 2018
Beyond cancer treatment: nurse specialists in the clinic 1:10
Beyond cancer treatment: nurse specialists in the clinic
Simon Crabb • 29 Nov 2018
TKIs for treating medullary thyroid cancer 2:59
TKIs for treating medullary thyroid cancer
Jolanta Krajewska • 29 Nov 2018
Changes in the staging system for HPV+ cancer patients 2:31
Changes in the staging system for HPV+ cancer patients
Hisham Mehanna • 29 Nov 2018
Weighing up efficacy data and QoL in clinical decision making 2:07
Weighing up efficacy data and QoL in clinical decision making
Joe O'Sullivan • 29 Nov 2018
Is RANGE providing the targeted therapies needed for urothelial cancer? 2:55
Is RANGE providing the targeted therapies needed for urothelial cancer?
Thomas Powles • 29 Nov 2018
The omega score: an emerging biomarker for risk determination 2:12
The omega score: an emerging biomarker for risk determination
Hisham Mehanna • 29 Nov 2018
Upcoming therapies in the metastatic urothelial carcinoma space 4:00
Upcoming therapies in the metastatic urothelial carcinoma space
Thomas Powles • 29 Nov 2018
Not enough attention paid to bone health in prostate cancer 2:18
Not enough attention paid to bone health in prostate cancer
Simon Crabb • 29 Nov 2018
How to involve patients in clinical decision making 2:04
How to involve patients in clinical decision making
Joe O'Sullivan • 29 Nov 2018
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT 1:23
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
Hisham Mehanna • 29 Nov 2018
Awaiting key results for enzalutamide and apalutamide in nmCRPC 1:55
Awaiting key results for enzalutamide and apalutamide in nmCRPC
Simon Crabb • 29 Nov 2018
A promising future for drug development in gastrointestinal cancer 1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker • 29 Nov 2018

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals